Shen Yun, Zhao Hao-Long, Du Juan, Li Yu-Ting, Tan Fang, Huang Cheng-Gang, Pei Gang
Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, PR China.
Clin Exp Pharmacol Physiol. 2005 Dec;32(12):1071-7. doi: 10.1111/j.1440-1681.2005.04314.x.
Feitai, a Chinese medicine formulation, has been shown to protect against lung fibrosis induced by bleomycin (BLM). In the present study, we investigated the effect of Feitai on transforming growth factor (TGF)-beta1 and monocyte chemoattractant protein-1 (MCP-1), which play important roles in the pathogenesis of BLM-induced lung fibrosis. The results demonstrated that Feitai could significantly attenuate BLM-induced acute lung inflammation and subsequent lung fibrosis. Meanwhile, the expression of MCP-1 and TGF-beta1 mRNA in the lungs increased in the BLM-treated group compared with the saline-instilled control group and Feitai treatment significantly decreased cytokine expression in BLM-treated mice. In addition, Feitai diminished the accumulation of MCP-1- and TGF-beta1-positive cells in lung tissues at the time of peak mRNA levels. In summary, the results of the present study indicate that treatment with Feitai ameliorates BLM-induced lung fibrosis, at least in part via the inhibition of MCP-1 and TGF-beta1 expression.
肺泰是一种中药制剂,已被证明可预防博来霉素(BLM)诱导的肺纤维化。在本研究中,我们研究了肺泰对转化生长因子(TGF)-β1和单核细胞趋化蛋白-1(MCP-1)的影响,这两种蛋白在BLM诱导的肺纤维化发病机制中起重要作用。结果表明,肺泰可显著减轻BLM诱导的急性肺部炎症及随后的肺纤维化。同时,与生理盐水灌注对照组相比,BLM治疗组肺组织中MCP-1和TGF-β1 mRNA的表达增加,而肺泰治疗显著降低了BLM治疗小鼠的细胞因子表达。此外,在mRNA水平达到峰值时,肺泰减少了肺组织中MCP-1和TGF-β1阳性细胞的积聚。总之,本研究结果表明,肺泰治疗可改善BLM诱导的肺纤维化,至少部分是通过抑制MCP-1和TGF-β1的表达来实现的。